Breaking News Instant updates and real-time market news.

ALXN

Alexion

$120.24

-1.1 (-0.91%)

16:35
10/19/16
10/19
16:35
10/19/16
16:35

Alexion's ALXN1007 granted orphan drug designation from FDA

Alexion Pharmaceuticals announced that the U.S. Food and Drug Administration has granted orphan drug designation to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of acute graft-versus-host disease. Alexion is currently investigating ALXN1007 in patients with acute GVHD of the lower gastrointestinal tract, a severe and life-threatening rare autoimmune disease that can occur as a complication of stem cell or bone marrow transplantation. "There is an urgent need for an effective treatment for GI-GVHD, which causes severe symptoms and often leads to mortality following allogeneic hematopoietic stem cell transplantation. Currently, even with best available care, about one-third of severely affected patients die from this devastating complication within six months of onset," said Martin Mackay, Ph.D., Executive Vice President and Global Head of R&D at Alexion. "Alexion is pleased that the FDA has granted orphan drug designation to ALXN1007, recognizing its potential to improve response rates in patients facing acute GI-GVHD." ALXN1007 is currently being evaluated in a Phase 2 study in patients with newly diagnosed acute GI-GVHD.

  • 27

    Oct

  • 02

    Nov

  • 06

    Nov

  • 11

    Nov

  • 14

    Dec

ALXN Alexion
$120.24

-1.1 (-0.91%)

09/23/16
WEDB
09/23/16
INITIATION
Target $132
WEDB
Neutral
Alexion initiated with a Neutral at Wedbush
Wedbush analyst Heather Behanna initiated Alexion with a Neutral and a $132 price target.
09/23/16
JEFF
09/23/16
NO CHANGE
Target $120
JEFF
Hold
Alexion price target lowered to $120 from $140 at Jefferies
Jefferies analyst Eun Yang lowered her price target for Alexion Pharmaceuticals to $120 after conducting a survey of 35 U.S. hematologists/nephrologists. The survey results support a cautious outlook on Soliris sales in 2021 and beyond due to potential competition, Yang tells investors in a research note. Specifically, 60% of those surveyed will shift away from Soliris to biosimilars if they are available due to cost, Yang tells investors in a research note. The analyst keeps a Hold rating on Alexion.
09/26/16
LEER
09/26/16
NO CHANGE
Target $211
LEER
Outperform
Alexion to dominate terminal complement inhibitor market, says Leerink
Leerink analyst Geoffrey Porges expects Alexion's flagship complement inhibition franchise to remain the dominant, if not only, terminal complement inhibitor on the market. The analyst notes that his research finds that the number of manufacturers with competing programs in early stage development face "significant" technical and market-related challenges to match or surpass Soliris. Porges continues to view Alexion's complement franchise as durable and capable of sustaining revenue growth throughout the mid-term as the company expands into other rare diseases. He reiterates an Outperform rating on the stock and raised his price target on the shares to $211 from $210.
10/04/16
BMUR
10/04/16
INITIATION
Target $221
BMUR
Buy
Alexion assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Alexion Pharmaceuticals with a Buy rating and $221 price target.

TODAY'S FREE FLY STORIES

NUGT

Direxion Gold Miners Bull

$34.72

1.73 (5.24%)

07:00
01/24/18
01/24
07:00
01/24/18
07:00
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.86

0.82 (4.55%)

06:59
01/24/18
01/24
06:59
01/24/18
06:59
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$20.92

-1.1 (-5.00%)

06:58
01/24/18
01/24
06:58
01/24/18
06:58
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEVA

Ceva

$48.35

0.05 (0.10%)

06:58
01/24/18
01/24
06:58
01/24/18
06:58
Downgrade
Ceva rating change  »

Ceva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$46.38

-2.19 (-4.51%)

06:58
01/24/18
01/24
06:58
01/24/18
06:58
Technical Analysis
Daily Junior Gold Miners Index Bear 3x Shares: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$54.85

-1 (-1.79%)

06:57
01/24/18
01/24
06:57
01/24/18
06:57
Earnings
Scientific Games sees Q4 revenue $820M-$825M, consensus $802.58M »

Scientific Games further…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$26.69

0.44 (1.68%)

06:57
01/24/18
01/24
06:57
01/24/18
06:57
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$88.04

0.54 (0.62%)

06:57
01/24/18
01/24
06:57
01/24/18
06:57
Recommendations
Wintrust Financial analyst commentary  »

Wintrust Financial price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$12.94

0.29 (2.29%)

, MU

Micron

$43.95

1.07 (2.50%)

06:56
01/24/18
01/24
06:56
01/24/18
06:56
Periodicals
AMD taps former Nvidia, Synaptics execs for graphics chip division, VB reports »

Advanced Micro Devices…

AMD

AMD

$12.94

0.29 (2.29%)

MU

Micron

$43.95

1.07 (2.50%)

NVDA

Nvidia

$238.91

5.22 (2.23%)

SYNA

Synaptics

$44.90

-0.45 (-0.99%)

INTC

Intel

$46.06

0.31 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 30

    Jan

  • 07

    Feb

  • 26

    Mar

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$141.82

-2.88 (-1.99%)

06:56
01/24/18
01/24
06:56
01/24/18
06:56
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$5.05

0.17 (3.48%)

06:56
01/24/18
01/24
06:56
01/24/18
06:56
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$18.11

0.96 (5.60%)

06:56
01/24/18
01/24
06:56
01/24/18
06:56
Recommendations
Immunomedics analyst commentary  »

Immunomedics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$133.48

-2.44 (-1.80%)

06:55
01/24/18
01/24
06:55
01/24/18
06:55
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$12.97

0.19 (1.49%)

06:55
01/24/18
01/24
06:55
01/24/18
06:55
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$39.85

0.16 (0.40%)

06:54
01/24/18
01/24
06:54
01/24/18
06:54
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CWST

Casella Waste

$24.26

0.09 (0.37%)

06:54
01/24/18
01/24
06:54
01/24/18
06:54
Upgrade
Casella Waste rating change  »

Casella Waste upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$20.44

-2.99 (-12.76%)

06:54
01/24/18
01/24
06:54
01/24/18
06:54
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$89.75

10.55 (13.32%)

06:53
01/24/18
01/24
06:53
01/24/18
06:53
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$43.66

-0.97 (-2.17%)

06:52
01/24/18
01/24
06:52
01/24/18
06:52
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$74.75

0.24 (0.32%)

06:51
01/24/18
01/24
06:51
01/24/18
06:51
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAP

Universal Stainless & Alloy

$22.85

0.44 (1.96%)

06:51
01/24/18
01/24
06:51
01/24/18
06:51
Earnings
Universal Stainless & Alloy reports Q4 EPS $1.06 with items vs. (22c) a year ago »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$25.13

-0.28 (-1.10%)

06:50
01/24/18
01/24
06:50
01/24/18
06:50
Hot Stocks
RPC, Inc. raises quarterly dividend by 43% to 10c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    May

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Hot Stocks
Baker Hughes CEO: Continue to see improvement in activity »

Lorenzo Simonelli, BHGE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$25.13

-0.28 (-1.10%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Earnings
RPC, Inc. reports Q4 adjusted EPS 27c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    May

PBYI

Puma Biotechnology

$90.90

-3.05 (-3.25%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Downgrade
Puma Biotechnology rating change  »

Cowen downgrades Puma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.